/NOT FOR DISTRIBUTION IN THE UNITED STATES OR THROUGH UNITED STATES WIRE
TORONTO, Nov. 25, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO)
("Biosign" or the "Company") is pleased to announce the following:
Biosign Schedules Investor Conference Call
Biosign is pleased to announce an Investor Conference Call, scheduled
for Wednesday, November 27th, 2013 at 11:00 AM Eastern Daylight Time. During this call, Biosign CEO Robert Kaul will read a prepared
statement commenting on recent news releases and providing additional
discussion on the Company's business plan. Following this presentation,
Mr. Kaul will answer a number of questions previously submitted from
participants regarding the business of the Company.
The conference call is open to any investor or stakeholder, including
shareholders, broker-dealers and other securities professionals. The
call will be recorded and available for review at
http://biosign.com/investors. To submit one or more questions to the
CEO, please email your question to firstname.lastname@example.org with the words
"Investor Question for Conference Call" in the subject line. Biosign
management will endeavour to address as many questions as possible in
the one-hour time period allocated to the call. To participate in the
call, please use the following login credentials:
Dial-In Number: 877-394-5901
Participant Code: 2169148
Date: November 27th, 2013 at 11:00 AM EDT
Biosign CEO Robert Kaul stated, "Throughout November, Biosign has made a
number of material announcements related to our business plan.
Management is pleased to be able to communicate with investors and
other interested parties in order to place these announcements into
greater context, and to address various stakeholder inquiries."
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, software
enabled health information solutions including the Pulsewave® Health Monitor and the Healthanywhere™ Patient monitoring /
self-management platform. The Company's Pulsewave® Health Monitor solution enables pulse wave data collection for
cardiovascular clinical decision support and self-care, while its
Healthanywhere™ solution offers industry-leading remote patient
monitoring and patient centred care management. The Company also offers
a number of cardiovascular screening programs for consumers under its
Heart Friendly™ brand, including Heart Friendly™ Practice, Heart
Friendly™ Dentist, and Heart Friendly™ Fitness. For more information on
Biosign, please visit www.biosign.com.
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in the company's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
For further information:
Biosign Contact Information:
Chief Executive Officer
Phone: (416) 218-9800 ext. 201